See more : Genesis Land Development Corp. (GDC.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Tenaya Therapeutics, Inc. (TNYA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tenaya Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- GFL Environmental Inc. (GFL.TO) Income Statement Analysis – Financial Results
- Isramco Negev 2 Limited Partnership (ISRA.TA) Income Statement Analysis – Financial Results
- Vail Resorts, Inc. (MTN) Income Statement Analysis – Financial Results
- Performance Drink Group, Inc. (PDPG) Income Statement Analysis – Financial Results
- Mota-Engil, SGPS, S.A. (EGL.LS) Income Statement Analysis – Financial Results
Tenaya Therapeutics, Inc. (TNYA)
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| Gross Profit | -8.69M | -8.71M | -4.03M | -2.48M | -1.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.04M | 94.54M | 54.39M | 31.10M | 23.15M |
| General & Administrative | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Other Expenses | 0.00 | 2.00K | -23.00K | 430.00K | 1.03M |
| Operating Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Cost & Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Interest Income | 7.06M | 1.95M | 108.00K | 87.00K | 453.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| EBITDA | -122.51M | -114.95M | -68.70M | -36.43M | -25.72M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -131.19M | -125.62M | -72.81M | -38.91M | -27.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.11M | 1.96M | 85.00K | 517.00K | 1.48M |
| Income Before Tax | -124.08M | -123.67M | -72.72M | -38.40M | -26.23M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.96K | -3.07M | -87.00K | -453.00K |
| Net Income | -124.08M | -123.66M | -69.65M | -38.31M | -25.78M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| EPS Diluted | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| Weighted Avg Shares Out | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
| Weighted Avg Shares Out (Dil) | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Tenaya Therapeutics Announces Research Leadership Updates
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
Source: https://incomestatements.info
Category: Stock Reports